Pro Share Advisors LLC Ngm Biopharmaceuticals Inc Transaction History

Pro Share Advisors LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.05 - $3.37 $75 - $242	72 Added 0.65%	11,069 $11,000
Q2 2023 Aug 10, 2023	BUY	$2.44 - $4.53 $1,342 - $2,491	550 Added 5.26%	10,997 $28,000
Q1 2023 May 11, 2023	SELL	$3.72 - $5.4 $5,632 - $8,175	-1,514 Reduced 12.66%	10,447 $42,000
Q4 2022 Feb 02, 2023	BUY	$3.41 - $12.93 $2,806 - $10,641	823 Added 7.39%	11,961 $60,000
Q3 2022 Nov 04, 2022	BUY	$12.59 - $17.67 $7,075 - $9,930	562 Added 5.31%	11,138 $145,000
Q2 2022 Aug 01, 2022	SELL	$10.58 - $17.5 $35,686 - $59,027	-3,373 Reduced 24.18%	10,576 $136,000
Q1 2022 May 10, 2022	SELL	$13.81 - $18.6 $53,596 - $72,186	-3,881 Reduced 21.77%	13,949 $213,000
Q4 2021 Feb 08, 2022	SELL	$17.26 - $22.02 $47,154 - $60,158	-2,732 Reduced 13.29%	17,830 $316,000
Q3 2021 Nov 12, 2021	SELL	$20.15 - $26.19 $29,217 - $37,975	-1,450 Reduced 6.59%	20,562 $432,000
Q2 2021 Aug 13, 2021	BUY	$15.06 - $30.03 $74,727 - $149,008	4,962 Added 29.1%	22,012 $434,000
Q1 2021 May 14, 2021	BUY	$24.99 - $31.93 $27,963 - $35,729	1,119 Added 7.02%	17,050 $496,000
Q4 2020 Feb 09, 2021	BUY	$16.21 - $31.44 $31,090 - $60,301	1,918 Added 13.69%	15,931 $483,000
Q3 2020 Nov 13, 2020	SELL	$15.59 - $19.97 $1,060 - $1,357	-68 Reduced 0.48%	14,013 $223,000
Q2 2020 Aug 03, 2020	BUY	$11.97 - $23.47 $41,535 - $81,440	3,470 Added 32.7%	14,081 $278,000
Q1 2020 May 15, 2020	SELL	$10.0 - $19.51 $71,120 - $138,755	-7,112 Reduced 40.13%	10,611 $131,000
Q4 2019 Feb 12, 2020	BUY	$9.97 - $20.28 $176,698 - $359,422	17,723 New	17,723 $328,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.